Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell, some substantial gains

June 21, 2017 6:05pm

Indexes also sing the tune, IBB up +4.12%, XBI up +4.71% as the XLV trails at +1.27%

As I had stated, my concern was the IBB and its ability to stay UP beyond the pre-market indication +0.1% … it did!

Time element of growth is momentum based

Pricing expectations are still in jeopardy as to the context of a sustainable breakout

Pre-open indications re-cap: 3 hit and 2 miss;

Out and about: ImmunoCellular Therapeutics (NYSEMKT: IMUC) Suspends further patient randomization for ICT-107 P3 Trial

I answer one question, in which company should investors commit and keep their money.

What have you missed, Wednesday’s results have implications to Thursday's sector activity.

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.

The advance/decline line scenario of 43 SCGT & RT covered companies:

· The open was positive with an A/DL of 30/9 and 4 flats;

· The mid-day was positive with an A/DL of 32/8 and 3 flat;

· The close was positive with an A/DL of 27/13 and 3 flats;

Pre-open indications re-cap: 3 hit and 2 miss

Juno Therapeutics (JUNO) closed up +$1.77 – hit;
Kite Pharma (KITE) closed up +$2.33 – hit;
Pluristem (PSTI) closed up +$0.06 – miss;
Regenxbio (RGNX) closed up +$0.95 – miss;
Sangamo Therapeutics (SGMO) closed down -$0.05 – hit;

Henry’omics:

From the pre-open’s investor’s newsletter … “the usual irrationality with “algo” dressing - the real question is how much are algorithms in control.”

Reiterating, “Just because the sector gets out of whack … doesn't mean you can’t … make money.”

I love it but, how long can it last …?

The SPDR S&P Biotech ETF (XBI) climbed 4.71%, putting it on track to post its best weekly performance since March 13.
The biotech ETF has already outperformed the broader market year to date, rising 30% in the period.
The rise in biotech helped the broader S&P health care sector rise about 1% on Wednesday.

ENJOY the high, next week will be the determinant as the month, quarter ends and many traders retreat to the July 4^th week … EARLY!

Out and about:

ImmunoCellular Therapeutics (NYSEMKT: IMUC) Suspend further patient randomization for ICT-107 P3 Trial

· IMUC has determined that it’s unable at this time to secure sufficient additional financial resources to complete the P3 registration trial of ICT-107;

· As a result, IMUC intends to suspend further patient randomization in the ICT-107 trial while it continues to seek a collaborative arrangement or acquisition of its ICT-107 program;

· IMUC plans to actively work with current collaborators to ensure that patients already randomized and receiving treatment in the P3 trial can be appropriately supported and followed;

· The suspension of the P3 registration trial of ICT-107 is expected to reduce the amount of cash used in IMUC's operations;

While maintaining the focus on its Stem-to-T-Cell research programs, ImmunoCellular continues its evaluation of financing and strategic alternatives for its immuno-oncology research and development pipeline and technology platform, which may include a potential merger, consolidation, reorganization or other business combination, as well as the sale of the company or the Company's assets.

IMUC closed DOWN -0.02 or -2.18% to $0.85

Daily analytics:

U.S. equities closed on Wednesday … with the DOW closing DOWN -0.25% (-53.14) as the NASDAQ closed UP +0.74% (+45.92) …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded again near 10.75 – DOWN -1.01% following …

· Tuesday trading near 10.86% - UP +4.73% after Monday traded 10.24 down -1.35%, Friday near 10.4, Thursday’s near 11 and last Wednesday ‘s near 10.6 …

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated a close of:

· Wednesday traded DOWN -0.25%

· Tuesday -1.01%

· Monday+0.74%

· Friday -0.25%

· Thursday -0.51%

· Last Wednesday -0.59%

… The iShares NASDAQ Biotechnology (IBB) indicated a close of:

· Wednesday traded UP +4.12%

· Tuesday +1.27%

· Monday +2.41%

· Friday -0.36%

· Thursday -0.77%

· Last Wednesday +0.56%

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %’s migrate……….

· Wednesday’s decliners ranged from -0.13% <OSIR> to -4.23% <VTGN> in 13 equities;

· Tuesday’s decliners ranged from -0.16% <BLCM> to -7.32% <BSTG> in 21 equities;

· Monday’s decliners ranged from -0.47% <ADRO> to -8.33% <ISCO> in 7 equities;

· Friday’s decliners ranged from -0.41% <NWBO> to -6.67% <CAPR> in 26 equities;

· Thursday’s decliners ranged from -0.60% <HSGX> to -9.67% <CAPR> in xx equities;

· Last Wednesday’s decliners ranged from -0.09% <BSTG> to -16.83% <IMUC> in 19 equities;

Versus

………… look at the percentage’s (%) and their decreases …….

· Wednesday’s gainers ranged from +0.38% <ONVO> to +12% <ATHX> in 27 equities;

· Tuesday’s gainers ranged from +0.31% <BLUE> to +8.61% <NWBO> in 20 equities;

· Monday’s gainers ranged from +0.20% <QURE> to +13.92% <FCSC> in 35 equities;

· Friday’s gainers ranged from +0.14% <KITE> to +8.11% <BLCM> in 14 equities;

· Thursday’s gainers ranged from +0.19% <CUR> to +4.69% <AST> in 10 equities;

· Last Wednesday’s gainers ranged from +0.40% <KITE> to +5.14% <FCSC> in 18 equities;

Some of MY working trend lines or indications for Tuesday:

… The greatest volume to the downside: SGMO, BLCM, CYTX, FSCS and AXGN

… Upside volume was weighted to: JUNO, ATHX, MDXG, NWBO and BLUE

… Biggest $ downside: BLCM, CLBS, AXGN, MESO and VTGN

… Largest $ upside: BLUE, KITE, JUNO, ONCE, and RGNX

… Flat: KOOL, RENE.L and ISCO

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

7 hours 1 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.